BRIEF-Astrazeneca says U.S. FDA accepts supplemental biologics license application for imfinzi
October 17, 2017 at 07:28 AM EDT
* U.S. FDA accepts supplemental biologics license application for imfinzi (durvalumab) in locally advanced, unresectable non-small cell lung cancer
